Clinical trials: CVA
Cerebral Infarction
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)
Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Trial name
- NCT00129805
- Testing
- MCI-9042, Aspirin
- Volunteers
- 1,510 people
- Sponsor
- Tanabe Pharma Corporation
Stroke, Brachial Plexus Injury
Outcome Measures Study on an Adult Myoelectric Elbow-Wrist-Hand Orthosis
The objective of this study is to evaluate the therapeutic and functional gains of a myoelectric elbow-wrist-hand orthosis for adult individuals with upper limb impairments using repeated measures studies that combines both gross…
- Conditions
- Stroke, Brachial Plexus Injury, Spinal Cord Injuries, Neurological Disease
- Trial name
- NCT04900896
- Testing
- Myoelectric Elbow-Wrist-Hand Orthosis
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Myomo
Acute Ischemic Stroke
Transcranial Ultrasound in Clinical SONothrombolysis
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue…
- Trial name
- TUCSON (NCT00504842)
- Testing
- MRX-801
- Where
- 14 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- ImaRx Therapeutics
Ischemic Stroke, Acute
Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symptom Onset
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus…
- Trial name
- FRIDA-CT (NCT07324837)
- Testing
- non-immunogenic staphylokinase
- Where
- 17 sites in Russia
- Volunteers
- 990 people
- Sponsor
- Supergene, LLC
Intracerebral Hemorrhage
A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage
The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.
- Trial name
- BIRCH (NCT05970224)
- Testing
- Ir-CPI
- Where
- 8 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Bioxodes S.A.
Acute Ischemic Stroke
Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)
A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke
- Trial name
- NCT06040476
- Testing
- hUCB
- Volunteers
- 39 people
- Sponsor
- StemCyte, Inc.
Subarachnoid Hemorrhage, Ruptured Intracranial Aneurysm
Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms
This is a randomized, double-blind, placebo-controlled, single-dose study investigating the safety and efficacy of NA-1 in patients with subarachnoid hemorrhage (SAH) undergoing endovascular repair of ruptured intracranial…
- Trial name
- ENACT-2 (NCT02056574)
- Testing
- NA-1
- Where
- 12 sites in United States, Canada
- Sponsor
- NoNO Inc.
Acute Ischemic Stroke
Study Evaluating Single Ascending Doses Of ILS-920
This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single…
- Trial name
- NCT00827190
- Testing
- ILS-920
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Aphasia, Global, Stroke
tDCS and Speech Therapy to Improve Aphasia
To study the effect of combined tDCS plus speech therapy compared to sham-tDCS plus speech therapy in subacute stroke patients suffering from moderate or severe aphasia.
- Conditions
- Aphasia, Global, Stroke, Transcranial Direct Current Stimulation, Speech Therapy
- Trial name
- MP-LOGA (NCT02395874)
- Testing
- tDCS + speech therapy
- Where
- Germany
- Volunteers
- 96 people
- Sponsor
- Medical Park AG
Ischemic Stroke, Stroke
Gravity Stent-Retriever System For Reperfusion Of Large Vessel Occlusion Stroke Trial
The study aims to evaluate the safety and efficacy of the Supernova stent retriever device, developed by Gravity Medical Technology, for treating acute ischemic stroke.
- Conditions
- Ischemic Stroke, Stroke, Cerebrovascular Disorders, Brain Diseases
- Trial name
- GRASSROOT (NCT06249776)
- Testing
- Supernova revascularization device
- Where
- 11 sites in India, Iran and 1 more
- Volunteers
- 55 people
- Sponsor
- Gravity Medical Technology, INC
Ischemic Stroke
A Safety Evaluation of the Use of Magnetic-guided Iron Particles
This study is a prospective trial wherein each included subject will receive the experimental magnetically enhanced diffusion therapy.
- Trial name
- NCT01519076
- Testing
- Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)
- Where
- 2 sites in Australia
- Volunteers
- 7 people
- Sponsor
- Pulse Therapeutics
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-1 (NCT01975376)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,745 sites in United States, Argentina and 34 more
- Volunteers
- 16,784 people
- Sponsor
- Pfizer
Acute Non-cardioembolic Ischemic Stroke
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in patients following a recent non…
- Trial name
- PACIFIC-STROKE (NCT04304508)
- Testing
- BAY2433334
- Where
- 197 sites in United States, Australia and 21 more
- Volunteers
- 1,808 people
- Sponsor
- Bayer
Pediatrics, Muscle Spasticity
BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity
This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric upper limb spasticity.
- Conditions
- Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke
- Trial name
- NCT01603615
- Testing
- Botulinum Toxin Type A
- Where
- 48 sites in United States, Canada and 7 more
- Volunteers
- 220 people
- Sponsor
- Allergan
Hemiparesis
Post-stroke Motor Rehabilitation Using Functional Near-infrared Spectroscopy-based Brain-computer-interface
Chronic stroke survivors suffering from weaknesses or movement difficulties in their hand/arm are provided a system to aid in at-home rehabilitation for 6 weeks.
- Trial name
- fNIRS-PROMOTE (NCT05258591)
- Testing
- Axem Home
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Axem Neurotechnology Inc.
Cerebral Infarction
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.
- Trial name
- NCT03176498
- Testing
- Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Stroke, Aphasia
Transcranial Alternating Current Stimulation in Post Stroke Aphasia Therapy
This study aims to investigate the efficacy of transcranial alternating current stimulation (tACS) combined with linguistic training for patients with chronic post-stroke aphasia.
- Trial name
- AfatES (NCT07510464)
- Testing
- active 75 Hz transcranial alternating current stimulation
- Where
- Poland
- Volunteers
- 11 people
- Sponsor
- QVITI S.A.
Acute Ischemic Stroke
A Single Ascending Dose of HRS-4029 in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.
- Trial name
- NCT06905314
- Testing
- HRS-4029
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Intracranial Aneurysm, Aneurysm
Coated Mongolian Aneurysm Treatment Study 2
The purpose of this study is to assess safety and effectiveness of the p64 MW HPC or p48 MW HPC Flow Modulation Device under prasugrel.
- Conditions
- Intracranial Aneurysm, Aneurysm, Vascular Diseases
- Trial name
- COMATS 2 (NCT04305704)
- Where
- Mongolia
- Volunteers
- 90 people
- Sponsor
- Phenox GmbH
Motor Disorders, Gait Disorders, Neurologic
Adherence to Long-term Exoskeleton Rehabilitation to Treat Lower Limb Weakness and / or Deficiencies in Adult Population
In 2019, approximately 2.4 billion people worldwide required rehabilitation for various health pathologies, a 63% increase since 1990.
- Conditions
- Motor Disorders, Gait Disorders, Neurologic, Neurodegenerative Diseases, Spinal Cord Injuries
- Trial name
- ALERT (NCT06538974)
- Testing
- Hands-free exoskeleton
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Wandercraft